Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Medivation, Inc.
Industry Pharmaceutical industry
Founded 2004
Headquarters San Francisco, California, United States
Owner Pfizer
Website medivation.com

Medivation is an American biopharmaceutical company focused on rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation, in collaboration with Astellas, is currently developing enzalutamide for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and Astellas announced that the U.S. Food and Drug Administration (FDA) granted approval to XTANDI® (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor. Medivation is headquartered in San Francisco, California, and it began operations in December 2004 with the acquisition of Medivation Neurology, Inc. The current CEO is David Hung.

Pfizer announced it would acquire the company in August 2016, and completed the acquisition the following month.

On March 3, 2010, Medivation's stock dropped $27.15 per share to close at $13.10, a 67% one-day decline on volume of 45 million shares. In response, a security fraud class-action lawsuit was initiatied by Izard Nobel LLP, alleging that Medivation made false and misleading statements regarding the effectiveness of Dimebon as a treatment for Alzheimer's disease, before being revealed that it did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer's disease.

The counsel for the case was Bernstein Liebhard and the lead plaintiffs were initially David Applestein then Catoosa Fund, LP. On March 22, 2012, the case was dismissed with prejudice. The plaintiffs appealed the dismissal in the Ninth Circuit Court of Appeals. The Ninth Circuit granted oral argument which will be held on Friday, January 17, 2014. On March 7, 2014, the Ninth Circuit affirmed the dismissal of the class action, Catoosa Fund LP v. Medivation, Inc., No. 12-15960. The Ninth Circuit stated "With the exception of the tenuous and unattributed statement that Dr. Schneider relates secondhand, plaintiff has not pled any facts supporting an inference of actual knowledge by defendants. Plaintiff relies heavily on the inference that, due to their positions, the defendants must have known about the unmatched nature of the study. That inference is entirely speculative and does not rise to the required strong inference; plaintiff's allegation is not at least as compelling as any opposing inference one could draw from the facts alleged."

In April the company was linked with a number of potential acquirers including Roche, AstraZeneca, Amgen and Gilead Sciences, and a possible hostile bid from Sanofi. AstraZeneca was reported to weigh in with an offer of £7 billion ($10 billion). On April 29, Sanofi launched a $9.3 billion takeover offer which was rejected by the Medivation board. In August, Pfizer announced that it would acquire the company for $14 billion or $81.50 per share, a 21% premium over the closing price on August 19; the acquisition was completed September 28.

EY Entrepreneur of the Year 2014 National Winner.

Investment goal date:
Dividends reinvested
Medivation, Inc. MDVN report Q2 2016
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q3 2016
2016-11-03
--
--
Q2 2016
2016-08-09
0.0000
-2.4500
Q1 2016
2016-05-05
0.1100
0.0300
Q4 2015
2016-02-25
0.2900
0.8500
Q3 2015
2015-11-05
0.3500
0.4700
Q2 2015
2015-08-06
0.2900
0.1600
Q1 2015
2015-05-07
0.0900
-0.0200
Q4 2014
2015-02-25
0.9800
1.0400
Q3 2014
2014-11-06
0.4800
0.4800
Q2 2014
2014-08-07
0.3000
0.3000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
300 NORTH CAPITAL, LLC
1823
Adamant Biomedical Investments AG
65000
Advisory Services Network, LLC
1116
Apex Capital Management
1277879
APIS CAPITAL ADVISORS, LLC
93500
BOSTON PRIVATE BANK & TRUST CO
27295
CHESAPEAKE PARTNERS MANAGEMENT CO INC/MD
305696
FolioMetrix LLC
5000
Hoxton Financial, Inc.
3732
Index Management Solutions, LLC
532
MANAGED ACCOUNT ADVISORS LLC
198252
NEW ENGLAND SECURITIES CORP /MA/
1000
Placemark Investments, Inc.
5218
ROYAL LONDON ASSET MANAGEMENT LTD
55538
RUSSELL FRANK CO/
22547
Major Shareholders
Name Relationship
Total Shares
Holding stocks
YARNO WENDY L
0.0400% (32742)
FALBERG KATHRYN E
0.0400% (32742)
BLICKENSTAFF KIM D
0.0200% (17742)
MDVN / TNDM /
Powell Andrew Kenneth William
0.0400% (28517)
CRTX / ITMN / MDVN /
Hung David
2.0200% (1549189)
MDVN / OPXA /
Machado Clarence Patrick
0.0900% (70792)
AAVL / CMRX / MDVN / SCYX /
Seely Lynn
0.1300% (96694)
MDVN /
Adams Daniel
0.0100% (5807)
MDVN /
Bailey Gregory
0.9000% (691101)
MDVN /
VERNON W ANTHONY
0.0200% (17742)
KRFT / MDVN / MKC / WWAV /
Kelsey Stephen Michael
0.0300% (21000)
GERN / MDVN /
Cohen Cheryl
0.0400% (32436)
CYTR / MDVN / TKAI / VTL /
Lobacki Joseph M
0.0300% (19365)
CPXX / MDVN /
Rhodes Jennifer J
0.0100% (11090)
ADMS / MDVN /
Graham Dawn
0.0300% (21206)
MDVN / PTCT / XENE /
Bierly Rick
0.0400% (28744)
IPXL / MDVN /
Yang Tseli Lily
0.0300% (22894)
MDVN /
Templeman Thomas
0.0300% (22720)
MDVN /
Hirmand Mohammad
0.0500% (40239)
MDVN /
King Michael L
0.0100% (9090)
MDVN /
% ()